Clinical Trials Logo

Clinical Trial Summary

The investigators hypothesise that parathyroid hormon (PTH) depletion interferes with normal activity of the hypothalamus-pituitary-adrenal (HPA)-axis and the renin-angiotensin-aldosterone-system (RAAS), which in turn may impact morbidity and quality of life. The main objective of the current study is to test if PTH deficiency influences the secretion of corticosteroids and whether any abnormalities in the HPA-axis and the RAAS-system can be reversed by PTH infusion.


Clinical Trial Description

Visit 1: Optimizing conventional treatment regarding s-magnesium, s-calcium, s-phosphorous and 25-hydroxyvitamin D (25(OH)D)-levels.

Visit 2 (In-hospital 4-7 days): Day one: 24h microdialysis sampling, venous blood sampling and 24h urine will be collected. Day 2: Start of PTH pump-treatment. Day 3-x: dose adjustment of PTH pump therapy according to Calcium Levels, the first two days after started PTH six daily venous blood-samplings will be performed. Day x: 24h microdialysis sampling and 24h urine-sampling and a venous blood sampling. Restart of conventional treatment.

The Control patients (healthy volunteers and patients with hyperparathyroidism) will perform 24h microdialysis-sampling only. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02986607
Study type Interventional
Source University of Bergen
Contact Marianne Astor, MD
Phone 40825265
Email marianne.astor@helse-bergen.no
Status Recruiting
Phase Early Phase 1
Start date March 2016
Completion date June 2018

See also
  Status Clinical Trial Phase
Completed NCT00379899 - ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis Phase 4
Completed NCT00377312 - 7 Day Continuous Parathyroid Hormone IV Infusion Phase 0
Completed NCT04040946 - Trial Comparing 2 Diagnostic Strategies for Preoperative Localization of Parathyroid Adenoma in Primary Hyperparathyroidism:TEMP / CT With Tc99m-sestaMIBI or PET / CT With F18-choline in First Intention Phase 3
Recruiting NCT03053999 - Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET)
Withdrawn NCT02711059 - Insulin Resistance in Primary Hyperparathyroidism N/A
Completed NCT01691781 - The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study N/A
Completed NCT00887666 - Pilot Study: Hypovitaminosis D, Hyperparathyroidism and Hypomagnesemia in Patients With Congestive Heart Failure N/A
Completed NCT00538720 - Effects of Vitamin D Replacement in Patients With Primary Hyperparathyroidism (PHPT) Phase 1
Terminated NCT03044600 - Gene Expression in Hyperparathyroidism
Completed NCT03747029 - Serum Calcium to Phosphorous (Ca/P) Ratio in the Diagnosis of Ca-P Metabolism Disorders: a Multicentre Study
Completed NCT01872429 - Short- and Long-Term Impact of Subtotal Parathyroidectomy on the Achievement of Bone and Mineral Parameters Recommended by Clinical Practice Guidelines in Dialysis Patients N/A
Completed NCT00800358 - Safety and Efficacy Study of Paricalcitol Versus Calcitriol in the Treatment of Secondary Hyperparathyroidism N/A
Recruiting NCT00169806 - Randall's Plaque Study: Pathogenesis and Relationship to Nephrolithiasis N/A
Completed NCT03968510 - Swalqol in Primary Hyperparathyroidism
Completed NCT00501215 - Effect of Parathyroidectomy on Sleep N/A
Completed NCT02591160 - Optimal HCTZ Cessation for Diagnosis of Hyperparathyroidism N/A
Recruiting NCT05299632 - F-18 PSMA for Localization of Parathyroid Adenoma
Completed NCT02432599 - Interest of the F18-choline as a Second Line of the Tracer for Detection of Parathyroid Adenomas Phase 2
Completed NCT02524041 - Association Between Serum Periostin Levels and Cortical Porosity in Patients With Secondary Hyperparathyroidism N/A
Recruiting NCT05667090 - Effects of Multiple Mega-dose of Vitamin D3 Supplementation on Ameliorating Moderate to Severe Chronic Pain in Hemodialysis Patients N/A